Activity Overview
This online, on-demand virtual symposium brings together renowned experts in advanced pancreatic ductal adenocarcinoma (PDAC). In this educational program, these experts discuss emerging approaches to target KRAS in advanced PDAC, framed in the discussion of challenging case scenarios where novel treatments could fit.
This educational activity is an archive of the live symposium held on April 11, 2026.
Target Audience
This educational activity is directed toward oncologists, nurse practitioners, physician assistants, nurses, pharmacists, and other health care providers involved in the diagnosis and treatment of pancreatic cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Interpret efficacy and safety data from recent and ongoing clinical trials of KRAS-targeted therapies for advanced PDAC
- Apply emerging clinical evidence, molecular profiling results, and patient-specific factors to guide the selection and sequencing of targeted therapies in advanced PDAC
E. Gabriela Chiorean, MD
Professor of Medicine, University of Washington
School of Medicine
Clinical Director, Gastrointestinal Oncology
Professor, Fred Hutchinson Cancer Center
Seattle, WA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AADi, Abbvie, BMS, Fortvita, GSK, Merus, Pfizer, Purple, Regeneron, Takeda, Verastem; Grant/Research Funding: Affini-T, BioAtla, BMS, Erasca, Genentech, Janssen, Lonza, Revolution Medicines, Sanofi, Sapience
Tanios S. Bekaii-Saab, MD
David F. and Margaret T. Grohne Professor of Novel
Therapeutics for Cancer Research I
Chair, Division of Hematology and Medical Oncology
Mayo Clinic in Arizona
Phoenix, AZ
Disclosures: Research Funding (to institution): Abgenomics, Agios, Arcus, Arys, Atreca, Bayer, Boston Biomedical, Bristol Myers Squibb, Celgene, Clovis, Eisai, Genentech, Incyte, Ipsen, Lilly, Merus, Mirati, Novartis, Pfizer, Seattle Genetics; Consulting (to institution): Arcus, Bayer, Eisai, Genentech, Incyte, Ipsen, Merck, Merus, Pfizer, Revolution Medicines, Seattle Genetics, Servier; Consulting (to self): AbbVie, Aptitude Health, AstraZeneca, BeiGene, Blueprint Medicines, Boehringer Ingelheim, Caladrius Biosciences, Celularity, Daiichi Sankyo, Deciphera, Exact Sciences, Exelixis, Foundation Medicine, GSK, Illumina, Janssen, Kanaph, Natera, Sanofi, Sobi, Stemline, Takeda, Treos Bio, Xilio, Zai Lab; IDMC/DSMB: 1Globe, AstraZeneca, Exelixis, FibroGen, Merck/Eisai, PanCAN; Suzhou Kintor, The Valley Hospital; Scientific Advisory Board: Artiva, Immuneering, Imugene, Replimune, Sun Biopharma, Xilis; Royalties: UpToDate; Inventions/Patents: WO/2018/183488: Human PD1 Peptide Vaccines and Uses Thereof: licensed to Imugene; WO/2019/055687: Methods and Compositions for the Treatment of Cancer Cachexia: licensed to Recursion
Mitesh Borad, MD
Professor of Medicine
Co-Leader, Novel Therapeutics and Therapeutic
Modalities Program
Mayo Clinic Comprehensive Cancer Center
Phoenix, AZ
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Accession Therapeutics, Amplia, Breakthru Bio, Cardinal Health, Cedilla, Cogent, Compass Therapeutics, Diffusion Pharmaceuticals, Eisai, Elevar, Exelixis, George Clinical, Guardant, Imugene, IMVAX, Jazz Pharmaceuticals, Kalivir Immunotherapeutics, Karkinos, Khora, Kriya Therapeutics, Merck, Moderna, Orum Therapeutics, Processa, RayzeBio, Reignite Therapeutics, Revolution Medicines, Senti Biosciences, Servier, Tempus, Vionix, Zielbio, ZymeWorks; Research Funding (to institution): Agios, Alentis Therapeutics, Arvinas, AstraZeneca, Basilea, Biond, Cogent, Compass Therapeutics, Elevar, Elevation, H3 Biomedicines, Incyte, Medinlink, Nuvectis, Pfizer, RayzeBio, Relay Therapeutics, Revolution Medicines, Sanofi, SeaGen, Tango Therapeutics; Stock Ownership: Abeona, ADC Therapeutics, Assertio, Homology
Christopher Lieu, MD
Professor of Medicine
Director, GI Medical Oncology
Associate Director for Clinical Research
University of Colorado Cancer Center
Aurora, CO
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient (paid to institution): Pfizer; Grant/Research Funding (paid to institution): Genentech, Sanofi
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here